Use biologic agents to induce remission in patients with moderately severe Crohn's disease

December 17, 2013, American Gastroenterological Association

The anti-TNF-α biologic agents, such as infliximab or adalimumab, are recommended to induce remission in patients with moderately severe Crohn's disease , according to a new guideline from the American Gastroenterological Association (AGA). Additionally, the guidelines recommend against using thiopurines or methotrexate alone to induce remission in these patients. The new guideline1 and accompanying technical review2 have been published in Gastroenterology, the official journal of the AGA Institute. The AGA Clinical Decision Support Tool, based on the guideline, can be reviewed at http://gastro.org/crohnsdecisiontool.

"Crohn's disease is a lifelong, relapsing disorder that can damage the bowel and lead to multiple abdominal operations over time. Deciding which medications are the best is a common dilemma for gastroenterologists and the Crohn's patients we treat. The disease can be disabling, but the drugs to control the disease can be toxic too and they can be costly. Balancing the benefits and the risks of the drugs and determining which medicines are most likely to keep the patient healthy is critical," according to Jonathan P. Terdiman, MD, lead author of the , and Chief of the Gastroenterology Service at the University of California, San Francisco Medical Center. "The new AGA guideline and clinical decision support tool will ease the decision process by providing transparent and actionable recommendations."

Crohn's disease is a chronic that causes significant morbidity and represents a considerable burden to society. It is estimated that 300,000 to 500,000 Americans suffer from Crohn's disease, costing the health-care system between $2.5 and $4 billion per year.

These guidelines are the first to make medication recommendations based on methodology that includes review of risks and benefits, patient preferences, and the quality of clinical evidence.

For the induction of remission, the guidelines recommend:

  • Using anti-TNF-α drugs to induce remission in patients with moderately severe Crohn's disease (strong recommendation, moderate-quality evidence).
  • Using anti-TNF-α monotherapy over thiopurine monotherapy to induce remission in patients who have moderately severe Crohn's disease (strong recommendation, moderate-quality evidence).
  • Using anti-TNF-α drugs in combination with thiopurines over thiopurine monotherapy to induce remission in patients who have moderately severe Crohn's disease (strong recommendation, high-quality evidence).

For maintenance of remission, the guidelines recommend:

  • Using thiopurines over no immunomodulator therapy to maintain a steroid-induced remission in patients with Crohn's disease (strong recommendation, moderate-quality evidence).
  • Using anti-TNF-α drugs over no anti-TNF-α drugs to maintain a steroid or anti-TNF-α -induced remission in with Crohn's disease (strong recommendation, high-quality evidence).

Explore further: Adalimumab is a promising therapy for children with Crohn's disease

More information: Read the "American Gastroenterological Association Institute Guideline on the Use of Thiopurines, Methotrexate, and Anti–TNF-a Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease" to review all of the treatment recommendations.

This guideline is AGA's first to practice AGA's new clinical guideline development process that employs the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. GRADE has been adopted by several national and international societies, including the AGA, and is becoming the common methodology for the streamlined and rigorous development of clear, transparent and actionable guidelines.

1 Terdiman J P et al. American Gastroenterological Association Institute Guideline on the Use of Thiopurines, Methotrexate, and Anti–TNF-a Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease. Gastroenterology 2013;145:1459.

2 Dassopoulos T et al. American Gastroenterological Association Institute Technical Review on the Use of Thiopurines, Methotrexate, and Anti–TNF-a Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease. Gastroenterology 2013;145:1464.

Related Stories

Adalimumab is a promising therapy for children with Crohn's disease

August 6, 2012
Adalimumab (an anti-tumor necrosis factor [TNF] antibody) is effective in maintaining remission in certain pediatric patients with Crohn's disease, according to a new study in Gastroenterology, the official journal of the ...

Drug improves remission of Crohn disease among children and adolescents

November 26, 2013
Among children and adolescents with Crohn disease not responding to treatment, use of the drug thalidomide resulted in improved clinical remission after 8 weeks of treatment compared with placebo, according to a study appearing ...

Probiotics do not prevent relapse in Crohn's disease patients

August 14, 2013
Despite previous data showing beneficial effects, the probiotic Saccharomuces boulardii (S. boulardii) does not prevent clinical relapse in patients with Crohn's disease, according to a new study in Clinical Gastroenterology ...

Two studies identify potential new drug for Crohn's disease and ulcerative colitis

August 21, 2013
Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. ...

Study finds potential new drug therapy for Crohn's disease

October 17, 2012
Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results in decreasing the debilitating effects of Crohn's Disease, according to researchers at the University of California San ...

Impaired sleep ups risk of relapse in Crohn's disease

August 8, 2013
(HealthDay)—For patients with Crohn's disease (CD), but not ulcerative colitis, sleep impairment is associated with increased risk of relapse, according to a study published in the August issue Clinical Gastroenterology ...

Recommended for you

Flu may be spread just by breathing, new study shows; coughing and sneezing not required

January 18, 2018
It is easier to spread the influenza virus (flu) than previously thought, according to a new University of Maryland-led study released today. People commonly believe that they can catch the flu by exposure to droplets from ...

New approach could help curtail hospitalizations due to influenza infection

January 18, 2018
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help ...

Certain flu virus mutations may compensate for fitness costs of other mutations

January 18, 2018
Seasonal flu viruses continually undergo mutations that help them evade the human immune system, but some of these mutations can reduce a virus's potency. According to new research published in PLOS Pathogens, certain mutations ...

Zika virus damages placenta, which may explain malformed babies

January 18, 2018
Though the Zika virus is widely known for a recent outbreak that caused children to be born with microencephaly, or having a small head, and other malformations, scientists have struggled to explain how the virus affects ...

Study reveals how MRSA infection compromises lymphatic function

January 17, 2018
Infections of the skin or other soft tissues with the hard-to-treat MRSA (methicillin-resistant Staphylococcus aureus) bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. ...

Fresh approach to tuberculosis vaccine offers better protection

January 17, 2018
A unique platform that resulted in a promising HIV vaccine has also led to a new, highly effective vaccine against tuberculosis that is moving toward testing in humans.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.